Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IRP1 deficiency alters mitochondrial metabolism and protects against metabolic syndrome pathologies
Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos
Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos
View: Text | PDF
Research Article Hepatology Metabolism

IRP1 deficiency alters mitochondrial metabolism and protects against metabolic syndrome pathologies

  • Text
  • PDF
Abstract

Iron regulatory protein 1 (IRP1) is a posttranscriptional regulator of cellular iron metabolism. In mice, loss of IRP1 causes polycythemia through translational de-repression of HIF2α mRNA, which increases renal erythropoietin production. Here, we show that Irp1–/– mice develop fasting hypoglycemia and are protected against high-fat diet–induced hyperglycemia and hepatic steatosis. Discovery-based proteomics of Irp1–/– livers revealed a mitochondrial dysfunction signature. Seahorse flux analysis in primary hepatocytes and differentiated skeletal muscle myotubes confirmed impaired respiratory capacity, with a shift from oxidative phosphorylation to glycolytic ATP production. This metabolic rewiring was associated with enhanced insulin sensitivity and increased glucose uptake in skeletal muscle. Under metabolic stress, IRP1 deficiency altered the redox balance of mitochondrial iron, resulting in inefficient energy production and accumulation of amino acids and metabolites in skeletal muscles, rendering them unavailable for hepatic gluconeogenesis. These findings identify IRP1 as a critical regulator of systemic energy homeostasis.

Authors

Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos

×

Figure 2

Irp1–/– mice are protected against high fat diet–induced liver steatosis.

Options: View larger image (or click on image) Download as PowerPoint

Irp1–/– mice are protected against high fat diet–induced liver steatosi...
For 10 weeks, 5-week-old male Irp1–/– mice and WT littermates (n = 6–19 per experimental group) were provided a control or high-fat diet (HFD) for 10 weeks. At the endpoint, the mice were euthanized, and livers were dissected for histological and biochemical analysis. (A) Images of representative mice and dissected livers after euthanasia. (B) Histopathological analysis of liver sections by staining with H&E for tissue architecture (top), Oil Red O (ORO) for neutral fats and lipids (middle), and periodic acid–Schiff (PAS) for glycogen (bottom); original magnification, ×20. (C) Heatmap of liver lipidomic changes between WT and Irp1–/– mice on HFD (n = 6 mice from each genotype). (D) Volcano plot of differentially expressed lipids in the liver of Irp1–/– and WT mice on HFD; P value threshold was set to 0.05 and fold change to 2. (E) Number of up- and down-regulated lipids in the liver of Irp1–/– versus WT mice on HFD. (F) qPCR analysis of liver Srebp1 mRNA expression. (G) Liver weight. (H) Hepatosomatic index (HSI). Quantitative data are presented as the mean ± SEM. Statistical analysis was performed with 2-way ANOVA with Tukey’s multiple-comparison test; comparisons between 2 groups were done with 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts